AstraZeneca’s Baxfendy Approval Isn’t a Hypertension Win — It’s a $40 Billion Market Wedge
FDA approved AstraZeneca's baxdrostat (Baxfendy) on May 18, 2026 — the first aldosterone synthase inhibitor for hypertension. Here's what...
AstraZeneca
AstraZeneca’s Tozorakimab Has Already Won the COPD Biologic Race — The Market Just Doesn’t Know It Yet
AstraZeneca's tozorakimab hit dual Phase III endpoints in COPD via OBERON and TITANIA, targeting a $1.68B biologic market with...
China Biotech Dealmaking Shifts from Opportunistic to Strategic
At BIO-Europe Spring 2026, industry leaders from AstraZeneca, Kelun-Biotech, Harbour BioMed, and Panacea Capital dissected the structural forces driving...